Investigation of Co-Q10 effect in acute myeloid leukemia

Investigation of Co-Q10 effect on TNF-a and IL-6 serum levels in patients with acute myeloid leukemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190924044867N1

Enrollment

Registered

2020-05-29

Start date

2020-06-04

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia. Acute myeloid leukemia with multilineage dysplasia

Interventions

Intervention 1: In a randomized, clinical trial, the intervention group of 32 patients receive a 200 mg loading dose COQ10 (Health Burst, USA) two days before the chemotherapy procedure. After that, a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 18 years of age AML approval by hematologists using Wright Gimsa, Sudan Block staining Subgroup approval by flow cytometry testing Having chemotherapy conditions

Exclusion criteria

Exclusion criteria: Receiving any antioxidant supplements for three months before starting chemotherapy Other malignancies than AML History of previous illness or infection, autoimmune disease, cancer, AIDS Receiving any previous chemotherapy

Design outcomes

Primary

Measure	Time frame
IL-6. Timepoint: Before and two months after the intervention. Method of measurement: Concentration of IL-6 in serum using ELISA kit.;TNF-a. Timepoint: Before and two months after the intervention. Method of measurement: Concentration of TNF-a in serum using ELISA kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Moasser

Shiraz University of Medical Sciences

emoasser@sums.ac.ir+98 917 104 8285

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026